Mantle Cell Lymphoma Treatment Market Enhancement in Medical Sector 2018 to 2026 Mantle Cell Lymphoma Treatment Market, by Therapy Type (Chemotherapy, Monoclonal Antibody Therapy, Targeted Therapy, Radiotherapy, and Stem Cell Transplant), by Route of Administration (Intravenous and Oral), and by End User (Hospitals, Clinics and Ambulatory Surgical Centers) and Geography Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026 Mantle cell lymphoma is a rare type of blood cancer, which occurs due to excessive growth of lymphocytes. Mantle cell lymphoma is one of the B-cell non-Hodgkin lymphoma, which occurs as a result of formation of tumors in the lymph nodes, which enters the blood and spreads to the bone marrow, digestive tract, spleen, and liver. Common symptoms of the disease include loss of appetite, weight loss, fever, nausea, and vomiting. The type of treatment for a patient suffering from mantle cell lymphoma depends on various factors such as the stage of disease, age, and overall health of the patient. In 2012, the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for bortezomib (Velcade), which updates the existing label to include subcutaneous method of administration for the treatment of mantle cell lymphoma (MCL) patients who have received at least one prior therapy. Click to Read More On Mantle Cell Lymphoma Treatment Market. Rising prevalence of mantle cell lymphoma is expected to accelerate growth of the mantle cell lymphoma treatment market over the forecast period Major factors driving growth of the mantle cell lymphoma market are rising prevalence of mantle cell lymphoma and increasing research and development activities in the healthcare sector resulting in a promising product pipeline. Key players operating the market include: Key players are offering products to cater to unmet needs in patients with relapsed or refractory mantle cell lymphoma. For instance, Kite Pharma, Inc. is focused on developing engineered autologous T cell therapy products for the treatment of cancer. In 2015, the company initiated Phase 2 clinical study of KTE-C19 in patients with relapsed or refractory mantle cell lymphoma. The global mantle cell lymphoma treatment market is segmented on the basis of therapy type, route of administration, end user, and geography. On the basis of therapy type, the global mantle cell lymphoma treatment market is segmented into: •Chemotherapy •Monoclonal Antibody Therapy •Targeted Therapy •Radiotherapy •Stem Cell Treatment On the basis of route of administration, the global mantle cell lymphoma treatment market is segmented into: •Intravenous •Oral Key players operating in the global mantle cell lymphoma treatment market include F.Hoffman La Roche Ltd., Abbvie, Inc., Kite Pharma, Inc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, GlaxoSmithKline Plc, Amgen, Inc., Gilead Sciences, Inc., and Johnson and Johnson. Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1148 Accelerated approval pathway program by the U.S. FDA is expected to propel the mantle cell lymphoma treatment market in North America Regional segmentation of the mantle cell lymphoma treatment market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be dominant in the global market over the forecast period. This is owing to increasing incidence rate of the disease in the region. According to the Leukemia and Lymphoma Society, 2014, about 70,800 new cases of cases of non-Hodkin Lymphoma were registered in the U.S., where mantle cell lymphoma represented about 6% or 4,200 cases of the total cases. Also, the FDA’s Center for Drug Evaluation and Research Agency works with manufacturers to analyze drug development, approval, promising the Breakthrough Therapy Destination Program to make treatments available for patients with rare disease. For instance, in 2013, the FDA approved Imbruvica (ibrutinib), manufactured by Janssen Pharmaceuticals, Inc. as a breakthrough therapy destination to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer. Asia Pacific is expected to witness high growth rate in the mantle cell lymphoma treatment market over the forecast period owing to rising government initiatives, rise in research and development to curb the disease. About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1–206–701–6702 Email: [email protected]
Mantle cell lymphoma is a rare type of blood cancer, which occurs due to excessive growth of lymphocytes. Mantle cell lymphoma is one of the B-cell non-Hodgkin lymphoma, which occurs as a result of formation of tumors in the lymph nodes, which enters the blood and spreads to the bone marrow, digestive tract, spleen, and liver.
© Copyright 2024 Paperzz
